COO – The Cooper Companies, Inc.

Investment Analysis of The Cooper Companies, Inc. – November 2025

Company Overview

The Cooper Companies, Inc. (NASDAQ: COO), headquartered in San Ramon, California, is a prestigious player in the Healthcare sector, primarily focusing on the Medical Instruments & Supplies industry. Established in 1958, Cooper operates through two main segments: CooperVision and CooperSurgical. CooperVision specializes in providing a diverse range of contact lenses, including toric and multifocal options designed for various vision challenges. Meanwhile, CooperSurgical commits to family and women’s health care, offering products and services that encompass fertility solutions, medical devices, and contraception globally. With total revenue reaching approximately $4.05 billion, The Cooper Companies demonstrates robust financial performance, solidifying its position within the healthcare market.

52-Week Price Performance Analysis

The 52-week chart of The Cooper Companies (COO) demonstrates a predominantly bearish trend, with the stock price depreciating from its peak of $110 to around $77.94, marking a significant decrease of approximately 24.34%. This decline showcases a persistent pattern of lower highs and lower lows, underlined by a strong descending trendline that has exerted resistance throughout much of the year.

Key Support and Resistance Levels

• Support Level: Approximately $70. This level has successfully absorbed downward price movements multiple times, signaling a potential floor where buyers emerge.
• Resistance Level: Staunch resistance has emerged close to the $90 mark, where the stock has faced challenges in breaking through.
• Current Price: The stock currently trades at $77.94, which is notably above its 52-week low of $61.78 but remains well below its 52-week high of $106.63.

The fifty-day moving average stands at $70.89, suggesting noteworthy short-term price trends. Its position below the current stock price implies recent upward momentum, indicating sustained positive investor sentiment or the onset of bullish trends. However, the analysis underlines the necessity of vigilance; while this shows potential for further gains, the proximity to historical highs warrants caution.

Given the bearish trend exhibited over the past year, potential investors should remain attentive to trading volume and price action, looking for validated breakouts to confirm a bullish reversal.

Financial Performance and Metrics

The financial health of The Cooper Companies is illustrated through several key metrics:
– Total Revenue: Approximately $4.05 billion.
– EBITDA: Roughly $1.11 billion, indicating solid operational performance and healthy cash flow.
– Current Stock Price: Currently at $77.94.
– Outstanding Shares: 198,808,921, with about 6,912,546 shares shorted, representing approximately 0.036% of the company’s float. This low short interest suggests that investor sentiment remains generally optimistic regarding the company’s future.

Analysts have projected a high target price of $96–a significant upside potential. The mean target price stands at $83, highlighting a consensus among financial analysts indicating the stock’s room for upward movement.

Recent News and Developments

There have been noteworthy developments surrounding The Cooper Companies:
– Jana Partners, an activist investor, has acquired a stake in Cooper and is advocating for strategic changes, including a potential merger of CooperVision with Bausch + Lomb. These moves aim to enhance competitiveness within the contact lens market.
– Browning West, LP, another major shareholder, has called for significant governance and strategic reforms, criticizing the current “growth at all costs” approach and suggesting a review of CooperSurgical’s direction.

Despite a strong earnings report with earnings per share (EPS) of $0.96, surpassing consensus estimates, the stock has faced declines of approximately 22.95% over the past year partly attributed to lowered growth forecasts in the contact lens market. To bolster shareholder confidence, the Board of Directors has approved a $2 billion share repurchase program, allowing the buyback of up to 15.4% of outstanding shares.

Market Sentiment and Analyst Recommendations

Analyst sentiment towards The Cooper Companies reflects a mixed outlook. JP Morgan recently downgraded their rating from “Overweight” to “Neutral,” lowering the target price from $110.00 to $76.00, which portrays a more cautious perspective on the company’s future prosperity. Conversely, Citi analyst Joanne Wuensch maintained a “Buy” rating with a target price of $104, signaling optimism about growth prospects.

The consensus rating among analysts currently leans towards a “Buy,” backed by a recommendation mean score of 2.21, implying a generally positive outlook. As institutional and retail investors assess their positions, both qualitative and quantitative metrics align to suggest that The Cooper Companies represents a viable opportunity for investment.

Conclusion

The Cooper Companies, Inc. stands at a critical juncture characterized by both opportunities and challenges within its operations and market positioning. The current stock price of $77.94, coupled with an optimistic target of $96, presents a compelling case for potential investors. However, the bearish trends, activist involvement, and mixed analyst sentiments signal that investors should proceed judiciously.

The development of the company’s strategic initiatives and market responses will be crucial in determining future performance. As always, it would be prudent for investors to consider their risk tolerance before making investment decisions.

Investing in The Cooper Companies offers prospective upside, bolstered by robust financial metrics and analyst forecasts; however, close monitoring of market trends and corporate governance will be essential as the situation unfolds.

Metric	Value
Market Cap	$15.6b
Total Debt	$2.5b
Total Cash	$124.9m
Shares Outstanding	198.8m
Float Shares	197.4m